Cancer treatment and monitoring methods using OX40 agonists

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9828432
SERIAL NO

14376998

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by correlation of the treatment and an increase in OX40-induced T cell proliferation.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
PROVIDENCE HEALTH & SERVICES - OREGON4805 NE GLISAN ST PORTLAND OR 97213

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Curti, Brendan Portland, US 1 38
Kovacsovics-Bankowski, Magdalena Portland, US 1 38
Walker, Ed Portland, US 1 38
Walker, Josh Portland, US 2 39
Weinberg, Andy Portland, US 2 49

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 28, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 28, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00